Author(s):
Madhuri Kowachi, Jyoti kumari, Anju Mishra
Email(s):
Email ID Not Available
DOI:
10.52711/0975-4377.2026.00030 
Address:
Madhuri Kowachi1, Jyoti kumari1, Anju Mishra2
1Student, Department of Pharmaceutics, School of Pharmacy, Chouksey Engineering College, Bilaspur Chhattisgarh, India.
2Assistant Professor, Department of Pharmaceutics, School of Pharmacy, Chouksey Engineering College, Bilaspur Chhattisgarh, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 3,
Year - 2026
ABSTRACT:
Formulation and evaluation of micro-capsules for peptic ulcers aim to create sustained-release systems often using polymers like chitosan guar gum, or HPMC, to prolong drug action in the stomach. Peptic ulcer disease is a common gastrointestinal disorder characterized by mucosal damage caused primarily by gastric acid, Helicobacter pylori infection, and prolonged use of non-steroidal anti-inflammatory drugs (NSAIDs). Conventional oral drug delivery systems often exhibit limited gastric residence time and reduced bioavailability, leading to suboptimal therapeutic outcomes. The present study focuses on the formulation and evaluation of drug-loaded microcapsules designed to enhance gastric retention, provide controlled drug release, and improve therapeutic efficacy in the management of peptic ulcer. Microcapsules were prepared using suitable polymers such as sodium alginate, chitosan, and ethyl cellulose by employing techniques like ionotropic gelation or solvent evaporation. The formulated microcapsules were evaluated for particle size, surface morphology, encapsulation efficiency, drug loading, swelling index, in-vitro drug release, and stability studies. Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) were performed to assess drug–polymer compatibility. In-vitro release studies were carried out in simulated gastric fluid (pH 1.2) to mimic gastric conditions. The results demonstrated that the optimized formulation exhibited uniform particle size distribution, high encapsulation efficiency, and sustained drug release over an extended period. Release kinetics followed a controlled diffusion mechanism, indicating the suitability of the formulation for prolonged gastric delivery. The study concludes that microencapsulation represents a promising approach for improving the therapeutic effectiveness of anti-ulcer drugs like lafutidine by enhancing bioavailability, reducing dosing frequency, and minimizing side effects.
Cite this article:
Madhuri Kowachi, Jyoti kumari, Anju Mishra. Formulation and Evaluation of Microcapsule for Peptic Ulcer Treatment. Research Journal of Pharmaceutical Dosage Forms and Technology.2026; 18(3):203-8. doi: 10.52711/0975-4377.2026.00030
Cite(Electronic):
Madhuri Kowachi, Jyoti kumari, Anju Mishra. Formulation and Evaluation of Microcapsule for Peptic Ulcer Treatment. Research Journal of Pharmaceutical Dosage Forms and Technology.2026; 18(3):203-8. doi: 10.52711/0975-4377.2026.00030 Available on: https://rjpdft.com/AbstractView.aspx?PID=2026-18-3-5
5 REFERENCES:
1. Malfer theiner P, Chan FK, McColl KE. Peptic ulcer disease. The lancet. 2009 Oct 24; 374(9699): 1449-61.
2. Lanas A, Chan FK. Peptic ulcer disease. The Lancet. 2017 Aug 5; 390(10094): 613-24.
3. Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med. 1994; 331: 717-27
4. Sverdén E, Agréus L, Dunn JM, Lager gren J. Peptic ulcer disease. Bmj. 2019 Oct 2; 367.
5. Dunlap JJ, Patterson S. Peptic ulcer disease. Gastro enterology Nursing. 2019 Sep 1; 42(5): 451-4.
6. Kamada T, Satoh K, Itoh T, Ito M, Iwamoto J, Okimoto T, Kanno T, Sugimoto M, Chiba T, Nomura S, Mieda M. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. Journal of Gastroenterology. 2021 Apr; 56: 303-22.
7. Bereda G. Peptic Ulcer disease: definition, patho physiology, and treatment. Journal of Biomedical and Biological Sciences. 2022; 1(2): 1-0.
8. Xie X, Ren K, Zhou Z, Dang C, Zhang H. The global, regional and national burden of peptic ulcer disease from 1990 to 2019: a population-based study. BMC Gastro Enterology. 2022 Feb 10; 22(1): 58.
9. Wu Y, Murray GK, Byrne EM, Sidorenko J, Visscher PM, Wray NR. GWAS of peptic ulcer disease implicates Helico bacter pylori infection other gastro intestinal disorders and depression. Nature Communications. 2021 Feb 19; 12(1): 1146.
10. Assefa B, Tadesse A, Abay Z, Abebe A, Tesfaye T, Tadesse M, Molla A. Peptic ulcer disease among dyspeptic patients at endo scopy unit, University of Gon.